Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
It is approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes, but it has also been prescribed off-label for weight loss purposes
Stay away from spots with visible veins, scars, stretch marks, tattoos, or any irritated skin, as these areas are more likely to bruise
Contact your healthcare provider promptly to assess symptoms and adjust treatment if necessary
GLP-1 receptor agonists may be appropriate for individuals who: Have a body mass index (BMI) of 35 kg/m or higher (or lower thresholds32.5 kg/m or abovefor people from Black, Asian, and other minority ethnic groups) and would benefit from weight loss Have established cardiovascular disease or are at high cardiovascular risk (certain GLP-1 receptor agonists have demonstrated cardiovascular benefits in clinical trials) Have chronic kidney disease (CKD) or heart failure, where specific agents may offer additional protection Require additional glucose-lowering therapy but wish to avoid weight gain associated with some other diabetes medicines Cannot tolerate or have contraindications to other glucose-lowering therapies NICE NG28 continuation criteria : GLP-1 receptor agonist therapy should be continued beyond 6 months only if the person has had a beneficial metabolic response , defined as a reduction of at least 11 mmol/mol (1.0%) in HbA1c and a weight loss of at least 3% of initial body weight
Understanding the long-term outcomes is critical for groups who are considering adding these therapies to coverage for weight loss so they can assess whether covering the cost of these therapies for their employees is affordable when long-term adherence and reduction in medical spend has yet to be established. Blue Cross and Blue Shield of Kansas continuously monitors the pharmacy landscape to determine the best course of care for members
Consider Probiotics
US$ 25.39
US$ 23.63
US$ 23.43
US$ 24.19
US$ 21.21
US$ 22.53
